XML 29 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Other Balance Sheet Details
 12 Months Ended
Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]  
Other Balance Sheet Details Other Balance Sheet Details
Inventory
Components of our inventory consists of the following:
December 31,
(In thousands)20212020
Raw materials$1,301 $391 
Work in process2,387 243 
Finished goods1,804 392 
Total$5,492 $1,026 
Prior to receiving FDA approval for Fintepla, we recorded all manufacturing product costs as research and development expense. As of December 31, 2021 and 2020, no write-downs of inventory were deemed necessary.
Other Current Assets
Other current assets consist of the following:
December 31,
(In thousands)20212020
Receivable for U.K. R&D tax relief scheme $12,359 $— 
Note receivable from Tevard5,000 — 
Receivable under collaboration agreement3,000 1,500 
Other4,376 3,436 
Total$24,735 $4,936 
Property and Equipment, Net
Property and equipment, net consists of the following:
 December 31,
(In thousands)20212020
Computer equipment and software$233 $429 
Leasehold improvements9,998 9,835 
Furniture and fixtures1,134 1,266 
Total11,365 11,530 
Less accumulated depreciation(4,168)(2,806)
Property and equipment, net$7,197 $8,724 
Depreciation expense for the years ended December 31, 2021, 2020 and 2019 was $1.6 million, $1.5 million, and $1.3 million, respectively.
Accrued and Other Current Liabilities
Accrued and other current liabilities consist of the following:
 December 31,
(In thousands)20212020
Accrued clinical trial costs
$13,537 $16,477 
Accrued compensation16,399 10,917 
Accrued milestone payment— 15,000 
Accrued license amendment fee
7,000 — 
Accrued royalties
4,250 479 
Other accrued liabilities14,227 12,091 
Total
$55,413 $54,964